Vir Biotechnology, Inc. Investing Cash Flow
Vir Biotechnology, Inc. (VIR) reported Investing Cash Flow of -$185.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- Vir Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$197.14M, a 449.20% decline year-over-year.
- Vir Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $11.84M, a 90.67% decline year-over-year.
- Vir Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $86.65M, a 38.43% decline year-over-year.
- Vir Biotechnology, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $40.45M, a 65.90% decline year-over-year.
- Vir Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $310.37M, a 37.85% decline from fiscal 2024.
- Vir Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $499.37M, a 203.33% increase from fiscal 2023.
- Vir Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $164.63M.
- Vir Biotechnology, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$1.19B.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$197.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$185.31M 10-Q · filed 2026-08-05 | -$98.66M derived: sum of 3 quarters · filed 2026-08-05 | -$58.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $11.84M 10-Q · filed 2026-05-07 | $98.49M derived: sum of 2 quarters · filed 2026-05-07 | $138.93M derived: sum of 3 quarters · filed 2026-05-07 | $195.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $86.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $127.10M derived: sum of 2 quarters · filed 2026-02-23 | $183.55M derived: sum of 3 quarters · filed 2026-08-05 | $310.37M 10-K · filed 2026-02-23 |
| 2025-09-30 | $40.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $96.90M derived: sum of 2 quarters · filed 2026-08-05 | $223.72M 10-Q · filed 2025-11-05 | $364.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $56.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $183.27M 10-Q · filed 2026-08-05 | $324.01M derived: sum of 3 quarters · filed 2026-08-05 | $442.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $126.82M 10-Q · filed 2026-05-07 | $267.56M derived: sum of 2 quarters · filed 2026-05-07 | $386.16M derived: sum of 3 quarters · filed 2026-05-07 | $597.76M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $140.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $259.34M derived: sum of 2 quarters · filed 2026-02-23 | $470.95M derived: sum of 3 quarters · filed 2026-02-23 | $499.37M 10-K · filed 2026-02-23 |
| 2024-09-30 | $118.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $330.21M derived: sum of 2 quarters · filed 2025-11-05 | $358.63M 10-Q · filed 2025-11-05 | $253.82M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $211.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $240.03M 10-Q · filed 2025-08-06 | $135.22M derived: sum of 3 quarters · filed 2026-02-23 | $76.26M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $28.42M 10-Q · filed 2025-05-08 | -$76.39M derived: sum of 2 quarters · filed 2026-02-23 | -$135.34M derived: sum of 3 quarters · filed 2026-02-23 | $94.97M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$104.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$163.76M derived: sum of 2 quarters · filed 2026-02-23 | $66.55M derived: sum of 3 quarters · filed 2026-02-23 | $164.63M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$58.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $171.36M derived: sum of 2 quarters · filed 2024-11-04 | $269.44M 10-Q · filed 2024-11-04 | $116.31M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $230.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $328.39M 10-Q · filed 2024-08-01 | $175.26M derived: sum of 3 quarters · filed 2025-02-27 | -$487.35M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $98.08M 10-Q · filed 2024-05-03 | -$55.06M derived: sum of 2 quarters · filed 2025-02-27 | -$717.66M derived: sum of 3 quarters · filed 2025-02-27 | -$989.99M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$153.13M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$815.74M derived: sum of 2 quarters · filed 2025-02-27 | -$1.09B derived: sum of 3 quarters · filed 2025-02-27 | -$1.19B 10-K · filed 2025-02-27 |
| 2022-09-30 | -$662.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$934.93M derived: sum of 2 quarters · filed 2023-11-03 | -$1.04B 10-Q · filed 2023-11-03 | -$1.42B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | -$272.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$377.72M 10-Q · filed 2023-08-04 | -$755.30M derived: sum of 3 quarters · filed 2024-02-26 | -$681.44M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | -$105.39M 10-Q · filed 2023-05-08 | -$482.97M derived: sum of 2 quarters · filed 2024-02-26 | -$409.12M derived: sum of 3 quarters · filed 2024-02-26 | -$333.74M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | -$377.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$303.72M derived: sum of 2 quarters · filed 2024-02-26 | -$228.35M derived: sum of 3 quarters · filed 2024-02-26 | -$140.81M 10-K · filed 2024-02-26 |
| 2021-09-30 | $73.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $149.23M derived: sum of 2 quarters · filed 2022-11-03 | $236.77M 10-Q · filed 2022-11-03 | $297.48M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $75.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $162.91M 10-Q · filed 2022-08-09 | $223.62M derived: sum of 3 quarters · filed 2023-02-28 | $38.24M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $87.53M 10-Q · filed 2022-05-05 | $148.25M derived: sum of 2 quarters · filed 2023-02-28 | -$37.13M derived: sum of 3 quarters · filed 2023-02-28 | -$26.55M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $60.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$124.67M derived: sum of 2 quarters · filed 2023-02-28 | -$114.08M derived: sum of 3 quarters · filed 2023-02-28 | -$9.86M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$185.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$174.79M derived: sum of 2 quarters · filed 2021-11-04 | -$70.58M 10-Q · filed 2021-11-04 | -$144.34M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $10.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $114.80M 10-Q · filed 2021-08-05 | $41.03M derived: sum of 3 quarters · filed 2022-02-28 | $88.33M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $104.22M 10-Q · filed 2021-05-06 | $30.45M derived: sum of 2 quarters · filed 2022-02-28 | $77.74M derived: sum of 3 quarters · filed 2022-02-28 | $122.22M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | -$73.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$26.48M derived: sum of 2 quarters · filed 2022-02-28 | $18.01M derived: sum of 3 quarters · filed 2022-02-28 | -$256.16M 10-K · filed 2022-02-28 |
| 2019-09-30 | $47.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $91.78M derived: sum of 2 quarters · filed 2020-11-10 | -$182.39M 10-Q · filed 2020-11-10 | -$166.29M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $44.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$229.68M 10-Q · filed 2020-08-11 | -$213.58M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | -$274.16M 10-Q · filed 2020-05-12 | -$258.07M derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $16.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$60.44M 10-K · filed 2021-02-25 | ||
| 2018-09-30 | -$76.54M 10-Q · filed 2019-11-19 | |||
| 2017-12-31 | -$29.99M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |